Mouhammed Amir Habra, M.D., F.A.C.P., F.A.C.E.

Peer-Reviewed Articles

1. Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, Habra MA, Graham P, Waguespack SG. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 108(5):1132-1142, 2023. e-Pub 2022. PMID: 36433823.
2. Sarvestani AL, Gregory SN, Teke ME, Terzolo M, Berruti A, Hernandez JM, Habra MA. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery. Ann Surg Oncol 30(2):680-682, 2023. e-Pub 2022. PMID: 36305989.
3. Landry JP, Clemente-Gutierrez U, Pieterman CRC, Chiang YJ, Waguespack SG, Jimenez C, Habra MA, Halperin DM, Fisher SB, Graham PH, Perrier ND. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery 172(2):559-566, 2022. e-Pub 2022. PMID: 35437162.
4. Murvelashvili N, Polanco PM, Khorsand SM, Marrero JA, Jia L, Mirfakhraee S, Else T, Habra MA, Cole S, Hamidi O. Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma. J Endocr Soc 6(8):bvac101, 2022. e-Pub 2022. PMID: 35811575.
5. Srougi V, Habra MA, Villares Fragoso MCB. Response to Letter to the Editor From de Ponthaud et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.". J Clin Endocrinol Metab 107(8):e3540, 2022. PMID: 35188202.
6. Srougi V, Habra MA, Fragoso MCBV. Response to Letter to the editor from Berruti et al.: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.". J Clin Endocrinol Metab 107(7):e3101-e3102, 2022. e-Pub 2022. PMID: 35302610.
7. Shirali AS, Zagzag J, Chiang YJ, Huang H, Zhang M, Habra MA, Grubbs EG, Fisher SB, Perrier ND, Lee JE, Graham PH. ASO Visual Abstract: Differences in the Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas. Ann Surg Oncol. e-Pub 2022. PMID: 35552937.
8. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
9. Shirali AS, Zagzag J, Chiang YJ, Huang H, Zhang M, Habra MA, Grubbs EG, Fisher SB, Perrier ND, Lee JE, Graham PH. Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas. Ann Surg Oncol. e-Pub 2022. PMID: 35499784.
10. Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers 14(3), 2022.
11. Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35158739.
12. Qdaisat A, Bedrose S, Ezzeldin O, Moawad AW, Yeung SJ, Elsayes KM, Habra MA. The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center. Front Endocrinol (Lausanne) 13:1023220, 2022. e-Pub 2022. PMID: 36457558.
13. Collins K, Oramas DM, Guccione J, Elsayes KM, Habra MA, Zhang M, Cheng L. Incidentally discovered myelolipomatous adrenal adenomas, including six cases presenting with hypercortisolism. Pathol Res Pract 224:153508. e-Pub 2021. PMID: 34119816.
14. Daher M, Habra MA. Visual Vignette. Endocr Pract 26(12):1524, 2020. PMID: 33471745.
15. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824391.
16. Majidi F, Martino S, Kondakci M, Antke C, Haase M, Chortis V, Arlt W, Ronchi CL, Fassnacht M, Laurent C, Petit JM, Casanovas O, Habra MA, Kanji A, Salvatori R, Ho ATN, Spyroglou A, Beuschlein F, Villa D, Limvorapitak W, Wahlin BE, Gimm O, Rudelius M, Schott M, Germing U, Haas R, Gattermann N. Clinical Spectrum of Primary Adrenal Lymphoma: Results of a Multicenter Cohort Study. Eur J Endocrinol. e-Pub 2020. PMID: 32567556.
17. Elsherif SB, Javadi S, Blair KJ, Morshid AI, Hui L, Khalaf AM, Elbanan MG, Zhang M, b|Habra MA, Elsayes KM. Preresection Radiologic Assessment and Imaging Features of 156 Pathologically Proven Adrenal Adenomas. J Comput Assist Tomogr. e-Pub 2020. PMID: 32345808.
18. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. e-Pub 2020. PMID: 32437031.
19. Mazzaglia PJ, Varghese J, Habra MA. Evaluation and management of adrenal neoplasms: endocrinologist and endocrine surgeon perspectives. Abdom Radiol (NY). e-Pub 2020. PMID: 32189021.
20. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
21. Bedrose S, Daher M, Altameemi L, Habra MA. Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions. Cancers (Basel) 12(2), 2020. e-Pub 2020. PMID: 32098326.
22. Ahmed AA, Elmohr MM, Fuentes D, Habra MA, Fisher SB, Perrier ND, Zhang M, Elsayes KM. Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. Clin Radiol. e-Pub 2020. PMID: 32089260.
23. Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. e-Pub 2020. PMID: 31900481.
24. Ahmed AA, Thomas AJ, Ganeshan DM, Blair KJ, Lall C, Lee JT, Morshid AI, Habra MA, Elsayes KM. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). e-Pub 2020. PMID: 31894378.
25. Smith DC, Kroiss M, Kebebew E, Habra MA, Chugh R, Schneider BJ, Fassnacht M, Jafarinasabian P, Ijzerman MM, Lin VH, Mohideen P, Naing A. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. e-Pub 2020. PMID: 31984451.
26. Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne) 11:594264, 2020. e-Pub 2020. PMID: 33329398.
27. Fisher SB, Habra MA, Chiang YJ, Wu SY, Graham PH, Grubbs EG, Lee JE, Perrier ND. Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Manual for Adrenocortical Carcinoma. World J Surg. e-Pub 2019. PMID: 31493191.
28. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
29. Elbanan MG, Javadi S, Ganeshan D, Habra MA, Rao Korivi B, Faria SC, Elsayes KM. Adrenal cortical adenoma: current update, imaging features, atypical findings, and mimics. Abdom Radiol (NY). e-Pub 2019. PMID: 31529204.
30. Elmohr MM, Fuentes D, Habra MA, Bhosale PR, Qayyum AA, Gates E, Morshid AI, Hazle JD, Elsayes KM. Machine learning-based texture analysis for differentiation of large adrenal cortical tumours on CT. Clin Radiol. e-Pub 2019. PMID: 31362884.
31. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological Risk Factors for Adrenocortical Carcinoma: A Hospital-based Case-Control Study. Int J Cancer. e-Pub 2019. PMID: 31241762.
32. Berruti A, Libè R, Laganà M, Ettaieb H, Sukkari MA, Bertherat J, Feelders RA, Grisanti S, Cartry J, Mazziotti G, Sigala S, Baudin E, Haak H, Habra MA, Terzolo M. Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. Eur J Endocrinol 180(5):311-320, 2019. PMID: 30970324.
33. Wannachalee T, Turcu AF, Bancos I, Habra MA, Avram AM, Chuang HH, Waguespack SG, Auchus RJ. The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumors. Clin Endocrinol (Oxf). e-Pub 2019. PMID: 31066920.
34. Morani AC, Jensen CT, Habra MA, Agrons MM, Menias CO, Wagner-Bartak NA, Shaaban AM, Roman-Colon AM, Elsayes KM. Adrenocortical hyperplasia: a review of clinical presentation and imaging. Abdom Radiol (NY). e-Pub 2019. PMID: 31093730.
35. Thomas AJ, Habra MA, Bhosale PR, Qayyum AA, Ahmed K, Vicens R, Elsayes KM. Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical carcinomas on computed tomography. Abdom Radiol (NY) 43(11):3101-3108, 2018. e-Pub 2018. PMID: 29671009.
36. Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268(1):172-178, 2018. e-Pub 2017. PMID: 28257320.
37. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. e-Pub 2018. PMID: 29996921.
38. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124(11):2365-2372, 2018. e-Pub 2018. PMID: 29656442.
39. Romero Arenas MA, Whitsett TG, Aronova A, Henderson SA, LoBello J, Habra MA, Grubbs EG, Lee JE, Sircar K, Zarnegar R, Scognamiglio T, Fahey TJ, Perrier ND, Demeure MJ. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Ann Surg Oncol 25(3):801-807, 2018. e-Pub 2017. PMID: 29218429.
40. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2017. PMID: 29161986.
41. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. PMID: 28911154.
42. Mathiesen JS, Habra MA, Bassett JHD, Choudhury SM, Balasubramanian SP, Howlett TA, Robinson BG, Gimenez-Roqueplo AP, Castinetti F, Vestergaard P, Frank-Raue K. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. J Clin Endocrinol Metab 102(6):2069-2074, 2017. PMID: 28323957.
43. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer 75:213-221, 2017. e-Pub 2017. PMID: 28237867.
44. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab:jc20162815. e-Pub 2016. PMID: 27662441.
45. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78(1):167-71, 2016. e-Pub 2016. PMID: 27286994.
46. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RG. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29(5):723-36, 2016. PMID: 27165744.
47. Altinmakas E, Guo M, Kundu UR, Habra MA, Ng C. Computed tomography and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography findings in adrenal candidiasis and histoplasmosis: Two cases. Clin Imaging 39(6):1115-8, 2015. e-Pub 2015. PMID: 26298420.
48. Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma. Cancer Res 75(19):4131-42, 2015. e-Pub 2015. PMID: 26282167.
49. Vodopivec DM, Habra MA, Ng C, Sircar K, Grubbs EG. Visual Vignette. Endocr Pract 21(7):854, 2015. e-Pub 2015. PMID: 26121444.
50. Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner B, Blonska M, Skerl S, Shao Y, Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra MA, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nat Commun 6:7530, 2015. e-Pub 2015. PMID: 26179207.
51. Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH. Impact of (18)F-FDG PET/CT on the management of adrenocorticol carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging 41(11):2066-73, 2014. PMID: 24990404.
52. Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG. Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role For Preoperative Chemotherapy. World J Surg 38(6):1318-27, 2014. e-Pub 2014. PMID: 24615603.
53. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
54. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients with Differentiated Thyroid Cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
55. Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. Surg Endosc. e-Pub 2013. PMID: 23765427.
56. Ejaz S, Shawa H, Henderson SA, Habra MA. Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. BMJ Case Rep 2013, 2013. e-Pub 2013. PMID: 23784764.
57. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone Metastases and Skeletal Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 98(4):1492-7, 2013. e-Pub 2013. PMID: 23436918.
58. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Metastatic Adrenocortical Carcinoma. Br J Cancer 108(4):826-30, 2013. e-Pub 2013. PMID: 23412108.
59. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. J Clin Endocrinol Metab 98(1):192-197, 2013. e-Pub 2012. PMID: 23150683.
60. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2012. PMID: 23185034.
61. Shawa H, Busaidy NL, Schellingerhout D, Habra MA. Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ Case Rep 2013, 2013. e-Pub 2013. PMID: 23682094.
62. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 2012. e-Pub 2012. PMID: 22965939.
63. Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [¹ F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol 30(26):e246-9, 2012. e-Pub 2012. PMID: 22649135.
64. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804-12, 2012. e-Pub 2011. PMID: 22006217.
65. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 2011. e-Pub 2011. PMID: 21412758.
66. Khan MI, Habra MA, McCutcheon IE, Nogueras-González GM, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract 17(5):717-26, 2011. PMID: 21454228.
67. Khan MI, Waguespack SG, Habra MA, Broaddus R, Jimenez C. Acute-Onset Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Metastatic Endometrioid Carcinoma of the Ovaries As a Fatal Complication. J Clin Oncol 29(16):e462-4, 2011. e-Pub 2011. PMID: 21422435.
68. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT Detecting Thyroid Plasmacytoma After the Successful Treatment of Gastric Large B-Cell Lymphoma. Clin Nucl Med 36(4):317-319, 2011. PMID: 21368613.
69. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 2011. e-Pub 2010. PMID: 21190975.
70. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple Endocrine Neoplasia Type 2B with a RET Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared With a RET M918T Mutation. Thyroid 21(2):189-192, 2011. e-Pub 2010. PMID: 21186952.
71. Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect?. J Travel Med 17(6):424-6, 2010. PMID: 21050326.
72. Habra MA, Núñez R, Chuang H, Ayala-Ramirez M, Rich T, Kyle K, Jimenez C. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine 37(1):209-212, 2010. e-Pub 2010. PMID: 20963572.
73. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14(9):1108-14, 2008. PMID: 19158050.
74. Habra MA, Weaver EJ, Prewitt PV. Primary cutaneous large B-cell lymphoma of the leg and acute hypercalcemia. J Clin Oncol 25(36):5825-6, 2007. PMID: 18089880.
75. Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA. Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol 82(4):299-303, 2007. PMID: 17094095.
76. Habra MA, Vassilopoulou-Sellin R. Contribution of routine chest x-ray in the long-term follow-up of patients with differentiated thyroid carcinoma. Thyroid 16(3):303-6, 2006. PMID: 16571094.
77. Picolos MK, Habra M, Safdar A, Sarlis NJ. Inactive pulmonary tuberculosis mimicking metastasis from papillary thyroid carcinoma in diagnostic radioiodine whole-body scintigraphy. Thyroid 15(9):1105-6, 2005. PMID: 16187924.
78. Habra MA, Vassilopoulou-Sellin R. Cervical spine metastasis mimicking thyroid bed uptake in follicular thyroid carcinoma. Thyroid 15(3):298-9, 2005. PMID: 15785252.
79. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 2004. PMID: 15287039.
80. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Protooncogene 891 Germline Mutation. J Clin Endocrinol Metab 89(8):4142-5, 2004. PMID: 15292360.
81. Habra MA, Hijazi R, Verstovsek G, Marcelli M. Medullary thyroid carcinoma associated with hyperthyroidism: a case report and review of the literature. Thyroid 14(5):391-6, 2004. PMID: 15186618.

Invited Articles

1. Rao SN, Habra MA. 5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications. Horm Cancer 7(1):17-23, 2016. e-Pub 2015. PMID: 26660146.
2. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47-55, 2016. e-Pub 2015. PMID: 26678514.
3. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arti-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111-22, 2014. PMID: 24891137.
4. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep. e-Pub 2013. PMID: 23674235.
5. Yeung SC, Habra MA, Thosani SN. Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med 17(4):260-8, 2011. PMID: 21577115.
6. Santarpia L, Habra MA, Jiménez C. Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies. Horm Metab Res 41(9):680-6, 2009. e-Pub 2009. PMID: 19343618.
7. Habra M, Sarlis NJ. Thyroid and aging. Rev Endocr Metab Disord 6(2):145-54, 2005. PMID: 15843886.

Editorials

1. Hajjar J, Habra MA, Naing A. Metformin: An Old Drug with New Potential. Expert Opinion on Investigational Drugs 22(12):1511-1517, 2013. PMID: 23978196.

Abstracts

1. Clifton GT, Habra MA, Aloia TA, Vauthey JN, Evans DB, Perrier ND, Grubbs EG, Lee JE. Effective surgical treatment of adrenal cortical carcinoma may not require routine regional lymphadenectomy. American Association of Endocrine Surgeons, 2015.
2. Romero Arenas MA, Whitsett TG, Aronova A, Henderson S, LoBello J, Habra MA, Grubbs EG, Lee JE, Sirkar K, Zarnegar R, Scognamiglio T, Fahey T, Perrier ND, Demeure MJ. Protein expression of PTTG1 as a diagnostic biomarker in Adrenocortical Carcinoma. American Association of Endocrine Surgeons, 2015.
3. Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, Hu M.I,Jimenez C,Kopetz S,Lee JE, Sherman S.I, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma—a need for molecular profiling to aid in prognostication and therapeutics. American Society of Clinical Oncology, 2015.
4. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Dutcus C, Xu J, Zhu J, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman S.I. Pharmacodynamic biomarkers of outcomes in the phase 3 study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). American Society of Clinical Oncology, 2015.
5. Naing A, Habra MA, Chugh R, Ijezrman M, Hesseltine E, Worden F, Phillips M, Smith D. Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001. ASCO Annual Meeting 2014, 2014.
6. Kutahyalioglu M, Elsayes K, Vicens RA, Sircar K, Jazaerly T, Ozsari L, Jimenez C, Waguespack SG, Busaidy NL, Cabanillas ME, Grubbs EG, Habra MA. Preexisting Adrenal Masses in patients with Adrenocortical Carcinoma: Byeond Size Alone. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014, 2014.
7. Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R, Dutcus C, de las Heras B, Zhu J, Habra MA, Newbold K, Shah M, Hoff AO, Gianoukakis AG, Kiyota N, Taylor M, Kim S-B, Krzyzanowska M, Sherman SI. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). ASCO Annual Meeting 2014, 2014.
8. Busaidy NL, Habra MA. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014:14952, 2014.
9. Fuentes-Mattei E, Phan L, Velazquez-Torres G, Wu W, SIrcar K, Wood CG, Hai T, Jimenez C, Cote G, Lee MH, Yeung SC J, Habra MA. Inhibition of HGF/cMet signaling as a therapeutic approach for adrenocortical cancer tumor progression and drug resistance. MDACC Divisoin of Medicine Research Retereat 2014, 2014.
10. Phan L, Feuntes-Mattei E, Velazquez-Torres G, Wu W, Sircar K, Wood CG, Hai T, Jiemenz C, Cote G, Lee MH, Yeung SC J, Habra MA. Hepatocyte Growth Factor and c-Met Signaling Promotes Growth of Adrenocortical Carcinoma. MDACC Divison of Medicine Research Reterat 2014, 2014.

Book Chapters

1. Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. In: Endocrine and Neuroendocrine Cancers. Cancers: Switzerland, 159-176, 2023.
2. Rothan SM, Habra MA, Elsayes KM. The incidental adrenal lesion. In: A practical and current approach for managing incidental findings. ARRS: Leesburg, Virginia, 2019.
3. Romero MA, Habra MA, Perrier ND. Adrenal Tumors. In: UICC Manual of Clinical Oncology. 9th. John Wiley & Sons Limited, 2016.
4. Hu MI, Jimenez C, Busaidy NL, Habra MA. Long-Term and Late Endocrine Effects of Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014.
5. Flores S, Habra MA. Thyroid Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014.
6. Thomas RM, Habra MA, Perrier ND, Grubbs EG. Well-Differentiated Carcinoma of the Thyroid and Neoplasms of the Parathyroid Glands. In: The M.D. Anderson Surgical Oncology Handbook. 5th. Lippincott Willimans& Wilkins, 2012.
7. Haddad RY, Habra MA. Cancer of the Endocrine System. In: Cancer Principles & Practice of Oncology Review. 3rd. Lippinctot Williams & Wilkins: Philadelphia, 2012.
8. Busaidy NL, Habra MA, Sellin RV. Endocrine Malignancies. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill: USA, 1039-1076, 2011.
9. Habra MA, Busaidy NL, Yeung J, Sellin RV. Endocrine and Metabolic Complications of Cancer Therapy. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill: USA, 1235-1255, 2011.
10. Schultz PN, Stava CJ, Habra MA, Sellin RV. Adult Long-term Follow-up. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill: USA, 1341-1350, 2011.
11. Haddad R, Habra MA. Cancer of Endocrine System. In: Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. 2nd. WoltersKluwer/Lippincot Williams & Wilkins: USA, 2009.
12. Habra MA, Vassilopoulou-Sellin R, Clayman G. Parathyroid Carcinoma. In: Advanced Therapy in Surgical Oncology. 1. B. C. Decker Incorporated, 2007.
13. Busaidy NL, Habra MA, Vassilopoulou-Sellin R. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology, 2006.
14. Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine Complications of Cancer Therapy. In: The MD Anderson Manual of Medical Oncology, 2006.
15. Amos KD, Habra MA, Perrier NC. Carcinoma of the Thyroid and Parathyroid Glands. In: The M.D. Anderson Surgical Oncology Handbook. 4th, 2006.
16. Habra MA. Chapter 21, In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review. In: Endocrine Tumors. 1, 2005.

Books (edited and written)

1. Habra MA, Vassilopoulou-Sellin R. M.D. Anderson Atlas of Endocrine Neoplasia, 2006.